Download PDF
Dtsch Med Wochenschr 2023; 148(19): 1236-1241
DOI: 10.1055/a-1939-0000
Dossier

Management der antibiotikaresistenten Tuberkulose

Management of drug-resistant tuberculosis
Christoph Lange
› Further Information
Also available at
    Permissions and Reprints

Die Verbreitung multiresistenter Tuberkulosebakterien erschwert die Kontrolle der Tuberkulose vor allem in der WHO-Region Europa. Seit 2022 gibt es dank neuer Medikamente aktualisierte Empfehlungen, um die Dauer der Therapie deutlich zu reduzieren. In diesem Beitrag werden neben der Epidemiologie und Diagnostik der antibiotikaresistenten Tuberkulose auch aktuelle Therapieempfehlungen vorgestellt.

Abstract

The spread of multidrug-resistant Mycobacterium tuberculosis bacteria jeopardizes tuberculosis control, especially in the WHO Europe region. Following the availability of novel drugs and treatment regimens the World Health Organization has updated management recommendations for patients affected by drug-resistant tuberculosis. These novel recommendations include a significant reduction in the duration of therapy. This review presents the epidemiology and diagnostics of antibiotic-resistant tuberculosis as well as up-to-date treatment recommendations.

Kernaussagen

  • Noch nie waren so viele Menschen auf der Welt gleichzeitig von einer Tuberkulose betroffen wie heute.

  • Basierend auf der Evidenz der Wirksamkeit von Zweitlinienmedikamenten hat die WHO die Definitionen für die antibiotikaresistente Tuberkulose neu festgelegt.

  • Die Standardtherapie der MDR/RR-TB mit BPaL (M) dauert nur noch 6 Monate.

  • Aktuell befinden sich 17 neue Medikamente in den Phasen I und II der klinischen Entwicklung.

  • Es bestehen erhebliche Probleme in der Implementierung einer neuen Diagnostik und Therapie in Hochinzidenzländern.

Schlüsselwörter

multiresistente Tuberkulose - extensiv-resistente Tuberlulose - Bedaquilin - Pretomanid

Keywords

multidrug-resistant tuberculosis - extensively drug-resistant tuberculosis - bedaquiline - pretomanid


Publication History

Article published online:
15 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 World Health Organization. Global tuberculosis report 2022. Geneva: Switzerland. 2022
    PubMedSearch in Google Scholar
  • 2 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399: 629-655
    CrossrefPubMedSearch in Google Scholar
  • 3 World Health Organization and the European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe 2023. Stockholm, Sweden. 2023
    PubMedSearch in Google Scholar
  • 4 Maier C, Chesov D, Schaub D. et al. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis. Clin Microbiol Infect 2023; 29 (06) 751-757
    CrossrefPubMedSearch in Google Scholar
  • 5 Dheda K, Lange C. A revolution in the management of multidrug-resistant tuberculosis. Lancet 2022; 400: 1823-1825
    CrossrefPubMedSearch in Google Scholar
  • 6 World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tubercu- losis treatment, 2022 update. Geneva: Switzerland. 2022
    PubMedSearch in Google Scholar
  • 7 World Health Organization, Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27–29 October 2020. Geneva: World Health Organization; 2021. CC BY-NC-SA 3.0 IGO.
    PubMed
  • 8 Roelens M, Migliori GB. et al. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med 2021; 204 (06) 713-722
    CrossrefPubMedSearch in Google Scholar
  • 9 Lange C, Aaby P, Behr MA. et al. 100 years of Mycobacterium bovis bacille Calmette-Guerin. Lancet Infect Dis 2022; 22 (01) e2-e12
    CrossrefPubMedSearch in Google Scholar
  • 10 Mack U, Migliori GB, Sester M. et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis ? A TBNET consensus statement. EurRespirJ 2009; 33: 956-973
    CrossrefPubMedSearch in Google Scholar
  • 11 Hamada Y, Gupta RK, Quartagno M. et al. Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis. EClinicalMedicine 2023; 56: 101815
    CrossrefPubMedSearch in Google Scholar
  • 12 World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: Switzerland IGO. 2020
    PubMedSearch in Google Scholar
  • 13 World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: Switzerland. 2021
    PubMedSearch in Google Scholar
  • 14 Dominguez J, Boeree MJ, Cambau E. et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis 2023; 23 (04) e122-e137
    CrossrefPubMedSearch in Google Scholar
  • 15 Dominguez J, Boettger EC, Cirillo D. et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016; 20 (01) 24-42
    CrossrefPubMedSearch in Google Scholar
  • 16 Dorman SE, Schumacher SG, Alland D. et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 2018; 18 (01) 76-84
    CrossrefPubMedSearch in Google Scholar
  • 17 Penn-Nicholson A, Georghiou SB, Ciobanu N. et al. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis 2022; 22 (02) 242-249
    CrossrefPubMedSearch in Google Scholar
  • 18 Hillemann D, RÅsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDR sl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-1772
    CrossrefPubMedSearch in Google Scholar
  • 19 Lange C, Dheda K, Chesov D. et al. Management of drug-resistant tuberculosis. Lancet 2019; 394: 953-966
    CrossrefPubMedSearch in Google Scholar
  • 20 Schaberg T, Brinkmann F, Feiterna-Sperling C. et al. Tuberculosis in adulthood – The Sk2-Guideline of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of adult tuberculosis patients. Pneumologie 2022; 76 (11) 727-819
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: Switzerland. 2022
    PubMedSearch in Google Scholar
  • 22 World Health Organization. WHO operational handbook on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, update. Geneva: Switzerland. 2022
    PubMedSearch in Google Scholar
  • 23 Conradie F, Bagdasaryan TR, Borisov S. et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med 2022; 387 (09) 810-823
    CrossrefPubMedSearch in Google Scholar
  • 24 Nyang’wa BT, Berry C, Kazounis E. et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med 2022; 387 (25) 2331-2343
    CrossrefPubMedSearch in Google Scholar
  • 25 Lange C, Duarte R, Frechet-Jachym M. et al. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. Am J Respir Crit Care Med 2016; 194 (08) 1029-1031
    CrossrefPubMedSearch in Google Scholar
  • 26 Lange C, Barry 3rd CE, Horsburgh Jr CR. Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel. Am J Respir Crit Care Med 2022; 205 (10) 1142-1144
    CrossrefPubMedSearch in Google Scholar
  • 27 Grobbel HP, Merker M, Kohler N. et al. Design of multidrug-resistant tuberculosis treatment regimens based on DNA sequencing. Clin Infect Dis 2021; 73 (07) 1194-1202
    CrossrefPubMedSearch in Google Scholar
  • 28 Mercier T, Desfontaine V, Cruchon S. et al. A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis. J Chromatogr B Analyt Technol Biomed Life Sci 2022; 1211: 123456
    CrossrefPubMedSearch in Google Scholar
  • 29 Heyckendorf J, Marwitz S, Reimann M. et al. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. Eur Respir J 2021; 58 (03) 2003492
    CrossrefPubMedSearch in Google Scholar
  • 30 Chesov E, Chesov D, Maurer FP. et al. Emergence of bedaquiline resistance in a high tuberculosis burden country. Eur Respir J 2022; 59 (03) 2100621
    CrossrefPubMedSearch in Google Scholar
  • 31 Koehler N, Andres S, Merker M. et al. Pretomanid-Resistant Tuberculosis. J Infect 2023; 86 (05) 520-524
    CrossrefPubMedSearch in Google Scholar
  • 32 Lange C, Kohler N, Gunther G. Regimens for Drug-Resistant Tuberculosis. N Engl J Med 2023; 388 (02) 190
    CrossrefPubMedSearch in Google Scholar
  • 33 Gunther G, Guglielmetti L, Leu C. et al. Availability and costs of medicines for the treatment of tuberculosis in Europe. Clin Microbiol Infect 2023; 29 (01) 77-84
    CrossrefPubMedSearch in Google Scholar